News Release

News Search

2020

* Information contained in this news release is current as of its date of announcement. Be aware that information contained herein is subject to change without notice.

Mitsui Fudosan’s First Overseas Rental Laboratory and Office Project
Decision to Participate in the Innovation Square Phase II (tentative name)
Project in Boston

January 16, 2020
Mitsui Fudosan Co., Ltd.

Key Points of the Project

  • Mitsui Fudosan participating in an overseas rental lab and office business for the first time
  • Cooperative project participation with Related Beal in Innovation Square Phase II (tentative name) in Boston
  • Major U.S. drug company Vertex Pharmaceuticals has decided to become a tenant in one building

Tokyo, Japan, January 15, 2020-Mitsui Fudosan Co., Ltd., a leading global real estate company headquartered in Tokyo, announced it participated in the Innovation Square Phase II (tentative name) rental lab and office business in Boston, a city in the U.S. state of Massachusetts, through its subsidiary, Mitsui Fudosan America, Inc. (CEO: John Westerfield).
Mitsui Fudosan is participating in an overseas rental lab and office business for the first time. The business partner company for this project is Related Beal, the Boston office of the Related Companies, Mitsui Fudosan’s partner for the redevelopment of Hudson Yards in Manhattan, New York.

Mitsui Fudosan started a rental lab and office business in Japan in May 2019, and decided to expand the business to Boston in the U.S. where a matured market has formed in the life science field for vigorous research and development. The Company plans to further expand its domestic and overseas rental lab and office business as infrastructure supporting research in life science field.

In association with participation in the project, Mitsui Fudosan has decided to rent an entire building to Boston-based Vertex Pharmaceuticals Inc. Vertex is a global life science company that has discovered, developed and brought to patients new medicines since its foundation in 1989, and has overseas bases in 13 countries, including the countries of the EU and Brazil. Vertex, which focuses on developing medicines to treat serious diseases such as cystic fibrosis*, sickle cell disease and type 1 diabetes is highly regarded in the market in particular for its development of four types of transformative medicines that expanded applicability to approx. 90% of cystic fibrosis patients.
* A genetic disorder designated as an incurable disease and afflicting approx. 1 in 2,500 people in the U.S. and Europe.

The Boston area, where this property is located, is an academic and economic center located in the U.S., and is growing significantly based on industries including healthcare and biotechnology. Notably, this property is located in the Seaport District, where redevelopment has advanced under the guidance of the City of Boston, and laboratories and offices have accumulated. In recent years, development of this neighborhood has moved ahead steadily to form a neighborhood following East Cambridge as Boston’s largest life science cluster, with new work areas, houses and entertainment areas coexisting closely.

This property also provides easy access by public transportation to South Station, Boston Logan International Airport and highways in and around Boston. In addition, the nearest bus stop is just one minute by foot, making it an outstanding location for transportation access.


Perspective drawing of Innovation Square Phase II (tentative name)

Mitsui Fudosan’s Overseas Strategy

Mitsui Fudosan Group’s long-term management policy, Vision 2025, includes the aim to evolve into a global company, and dramatic growth overseas is expected in the future. Mitsui Fudosan has thus far expanded its operations to the U.S. and the UK, as well as places such as China, Taiwan and Southeast Asia. In the U.S., Mitsui Fudosan is engaged in business developments including offices, rental housing, participating in rental housing business such as 55 Hudson Yards, which opened in Manhattan, New York, in October 2018. Mitsui Fudosan is expanding business in multiple cities while aiming to capture further business opportunities going forward.

Overview of the property

Property Name Innovation Square Phase II (tentative name)
Location 316 - 318 Northern Avenue, Boston, Massachusetts
Scale 4 floors above ground and 1 below
Site Area Approx. 98,000 ft2 (approx. 9,100 m2)
Total Floor Area Approx. 306,000 ft2 (approx. 28,400 m2)
Total Rental Area Approx. 269,000 ft2 (approx. 25,000 m2)
Purpose Laboratories, offices, and shops
Schedule Construction from 2020
Completion in 2021 (planned)

Map

Wide area map

Close-up view

Business developments in the Boston area

290 Revolution Drive (tentative name)

Location 290 Revolution Dr, Somerville, MA
Completion 2021 (planned)
Site Area Approx. 71,900 ft2 (approx. 6,700m2)
Total Floor Area Approx. 425,400 ft2 (approx. 39,500m2)
No. of Floors 8 floors above ground
Purpose Rental housing, stores
Overview Co-development with business partner from 2019

Laboratory and office business developments in Japan

Mitsui Link Lab Kasai (within Daiichi Sankyo Kasai R&D Center)

Location 1-16-13 Kitakasai, Edogawa-ku, Tokyo (residential address)
Completion* End of January 2020 (planned)
Site Area Entire facility: Approx. 603,300 ft2 (56,044.5 m2)
Rental Area Approx. 24,200 ft2 (2,248.71 m2)
(Bldg. No. 5, 2nd to 4th floors)
Purpose Laboratories
Overview Mitsui Fudosan subleases to tenants part of a leased building owned by Daiichi Sankyo Co., Ltd. (master leasing business)

* Scheduled completion of renovation.

Mitsui Link Lab Shinkiba (tentative name)

Location (Lot number) 2-3-13 Shinkiba, Koto-ku, Tokyo
Completion April 2021 (planned)
Site Area Approx. 35,500 ft2 (3,300.06 m2)
Rental Area Approx. 84,000 ft2 (approx. 7,800 m2)
Purpose Laboratories and offices
Overview Mitsui Fudosan provides leased land from the land owner to tenants after developing the building

Mitsui Link Lab Kashiwa-no-ha (tentative Name)

Location 6-6-1 Kashiwanoha, Kashiwa, Chiba Prefecture
Completion 2021 (planned)
Site Area 193,800 ft2 (18,000 m2)
Purpose Laboratories